Dutasteride in localised prostate cancer management: The REDEEM randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 379, Issue 9821, 2012, Pages 1103-1111

  Fleshner, Neil E ^a   Lucia, M Scott ^b   Egerdie, Blair ^c   Aaron, Lorne ^d   Eure, Gregg ^e   Nandy, Indrani ^f   Black, Libby ^f   Rittmaster, Roger S ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Urologic Medical Research   (Canada)

^d Urology South Shore Research   (Canada)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PLACEBO;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

EID: 84859108456     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61619-X     Document Type: Article

References (30)

1. American Cancer Society Cancer facts and figures http://www.cancer.org/ docroot/STT/content/STT-1x-Cancer-Facts-and-Figures-2008.asp 2008 (accessed Dec 23, 2008).
2. N Howlader, AM Noone, M Krapcho et al. SEER cancer statistics review, 1975-2008, National Cancer Institute http://seer.cancer.gov/csr/1975-2008/ (accessed Aug 30, 2011).
3. L Klotz, L Zhang, A Lam, R Nam, A Mamedov, A Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
4. N Fleshner, AR Zlotta Prostate cancer prevention: past, present, and future Cancer 110 2007 1889 1899 (Pubitemid 350036848)
5. R Etzioni, DF Penson, JM Legler et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990 (Pubitemid 34814727)
6. FH Schröder, J Hugosson, MJ Roobol and the ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
7. YH Shao, PC Albertsen, CB Roberts et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml Arch Intern Med 170 2010 1256 1261
8. DA Barocas, JE Cowan, JA Smith Jr, PR Carroll and the CaPSURE Investigators What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database J Urol 180 2008 1330 1334
9. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection, USA; 2010. Version 2 http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf (accessed Sept 10, 2011).
10. GL Lu-Yao, PC Albertsen, DF Moore et al. Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202 1209
11. CG Roehrborn, P Boyle, JC Nickel, K Hoefner, G Andriole and the ARIA3001 ARIA3002 and ARIA3003 Study Investigators Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 60 2002 434 441 (Pubitemid 35292169)
12. M Gleave, J Qian, C Andreou et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer - results from a 4-month pre-radical prostatectomy study Prostate 66 2006 1674 1685 (Pubitemid 44646358)
13. GL Andriole, DG Bostwick, OW Brawley and the REDUCE Study Group Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
14. N Fleshner, LG Gomella, MS Cookson and the REDEEM Study Group Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial Contemp Clin Trials 28 2007 763 769 (Pubitemid 47499254)
15. JI Epstein, WC Allsbrook Jr, MB Amin, LL Egevad and the ISUP Grading Committee The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242 (Pubitemid 41232997)
16. AJ Roth, B Rosenfeld, AB Kornblith et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer Cancer 97 2003 2910 2918 (Pubitemid 36605162)
17. C Warlick, BJ Trock, P Landis, JI Epstein, HB Carter Delayed versus immediate surgical intervention and prostate cancer outcome J Natl Cancer Inst 98 2006 355 357 (Pubitemid 43338215)
18. MC Somerville, JB Shannon, TH Wilson Chapter 17: Design, summarization, analysis and interpretation of cancer prevention trials KE Peace Design and analysis of clinical trials with time-to-event endpoints 2009 Chapman and Hall Boca Raton, Florida 387 420
19. A Finelli, G Trottier, N Lawrentschuk et al. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer Eur Urol 59 2011 509 514
20. JM Chan, V Weinberg, MJ Magbanua et al. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer Cancer Causes Control 22 2011 141 150
21. MS Stratton, AM Algotar, J Ranger-Moore et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer Cancer Prev Res (Philadelphia) 3 2010 1035 1043
22. RW deVere White, A Tsodikov, EC Stapp, SE Soares, H Fujii, RM Hackman Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer Nutr Cancer 62 2010 1036 1043
23. J Frattaroli, G Weidner, AM Dnistrian et al. Clinical events in prostate cancer lifestyle trial: results from two years of follow-up Urology 72 2008 1319 1323
24. DG McLeod, P Iversen, WA See, T Morris, J Armstrong, MP Wirth and the Casodex Early Prostate Cancer Trialists' Group Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 97 2006 247 254
25. P Pinsky, H Parnes, L Ford Estimating rates of true high-grade disease in the prostate cancer prevention trial Cancer Prev Res (Philadelphia) 1 2008 182 186
26. IM Thompson, PJ Goodman, CM Tangen et al. The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224 (Pubitemid 36859473)
27. IM Thompson, C Chi, DP Ankerst et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128 1133 (Pubitemid 44288787)
28. CG Roehrborn, GL Andriole, TH Wilson, R Castro, RS Rittmaster Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial Eur Urol 59 2011 244 249
29. HB Carter, A Kettermann, C Warlick et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience J Urol 178 2007 2359 2364
30. GL Andriole, D Bostwick, OW Brawley and the REDUCE Study Group The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study J Urol 185 2011 126 131